Kapila K. Anand - 31 Mar 2023 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Director
Signature
/s/ Catherine S. Powell, as Attorney-in-Fact for Kapila K. Anand
Issuer symbol
ELAN
Transactions as of
31 Mar 2023
Transactions value $
$28,750
Form type
4
Filing time
05 Jul 2023, 17:12:11
Previous filing
02 Dec 2022
Next filing
07 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Deferred Stock Units Award $14.4K +1.53K +104.88% $9.40 2.99K 31 Mar 2023 Common Stock 1.53K Direct F1, F2, F3
transaction ELAN Deferred Stock Units Award $14.4K +1.43K +47.83% $10.06 4.42K 30 Jun 2023 Common Stock 1.43K Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
F2 The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
F3 The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $9.40 on March 31, 2023.
F4 The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $10.06 on June 30, 2023.